- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00002766
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone ("ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.
PURPOSE: This randomized phase III trial is studying two different chemotherapy regimens and comparing them to see how well they work in treating adults with acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.
Studieoversikt
Status
Intervensjon / Behandling
- Legemiddel: cyklofosfamid
- Stråling: strålebehandling
- Legemiddel: mitoksantronhydroklorid
- Legemiddel: prednison
- Legemiddel: cytarabin
- Legemiddel: daunorubicinhydroklorid
- Legemiddel: etoposid
- Legemiddel: metotreksat
- Legemiddel: vinkristinsulfat
- Legemiddel: merkaptopurin
- Legemiddel: doksorubicinhydroklorid
- Biologisk: sargramostim
- Legemiddel: karmustin
- Biologisk: daktinomycin
- Legemiddel: pegaspargase
Detaljert beskrivelse
OBJECTIVES:
- Compare the incidence of complete remission (CR) following induction with the ALL-2 regimen (cytarabine and high-dose mitoxantrone) vs the L-20 regimen (vincristine and prednisone) in previously untreated adult patients with acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma, and lymphoid blast crisis chronic myelogenous leukemia.
- Compare the time to CR, length of hospital stay, efficacy of treatment in Philadelphia chromosome-positive ALL, and the proportion of patients achieving durable (greater than 5 years) remission in each treatment regimen.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating institution and antecedent lymphoid blast crisis of chronic myelogenous leukemia (yes vs no). Patients are randomized to one of two treatment arms.
Arm I:
- Patients receive induction therapy consisting of cytarabine IV over 3 hours on days 1-5 with high-dose mitoxantrone IV on day 3 and methotrexate intrathecally on days 2 and 4. Patients receive sargramostim (GM-CSF) subcutaneously or IV over 4 hours beginning on day 7 and continuing until blood counts recover.
- At 7-14 days following induction therapy, patients receive consolidation therapy consisting of vincristine IV on days 1, 8, 15, 22, and 29, oral prednisone 2-3 times daily on days 1-30 and methotrexate intrathecally on days 8, 15, 22, and 29.
- At 2-3 weeks following the last dose of vincristine, patients receive an additional course of consolidation therapy consisting of cyclophosphamide IV on day 1 and GM-CSF subcutaneously beginning on day 3 and continuing until blood counts recover.
- At 3-4 weeks following the second consolidation course, patients receive a third course of consolidation therapy consisting of cytarabine IV bolus on day 1 followed by continuous infusion cytarabine on days 1-4 with etoposide IV over 1 hour on days 1-3 and methotrexate intrathecally on days 2 and 4. Patients receive GM-CSF subcutaneously beginning on day 6 and continuing until blood counts recover.
- Following recovery from the third consolidation course, patients receive a fourth consolidation course consisting of pegaspargase IV or intramuscularly (IM) on day 1.
- Following recovery from consolidation therapy patients receive 2 sequences of maintenance therapy with sequence one consisting of vincristine IV on days 1 and 8, oral prednisone 2-3 times daily on days 1-8, doxorubicin IV on day 15, oral mercaptopurine 2-3 times daily on days 36-64, oral methotrexate on days 39, 46, 53, and 60, dactinomycin IV on day 85, and methotrexate intrathecally on days 36 and 43.
- At 2 weeks following sequence one of maintenance therapy, patients receive sequence two consisting of the same regimen as in the first sequence with the addition of cyclophosphamide IV and carmustine IV on day 15.
- Patients with CNS involvement receive whole brain radiotherapy in addition to chemotherapy regimens.
Arm II:
- Patients receive induction therapy consisting of vincristine IV on days 1, 8, 15, 22, and 29, oral prednisone 2-3 times daily on days 1-29, cyclophosphamide IV on day 5, doxorubicin IV on days 23-25 and 42, methotrexate intrathecally on days 3, 5, 13, 16, 32, and 34 and GM-CSF subcutaneously or IV over 4 hours beginning from days 7 and 27 and continuing until blood counts recover.
- At approximately 3 weeks following induction therapy, patients receive consolidation therapy consisting of cytarabine IV bolus on day 1 followed by continuous infusion cytarabine on days 1-5, with daunorubicin IV on days 1-3 and methotrexate intrathecally on days 2 and 4. Patients receive GM-CSF subcutaneously beginning on day 7 and continuing until blood counts recover.
- At 6-8 weeks following the first course of consolidation therapy, patients receive a second consolidation course consisting of cytarabine IV bolus on day 1 followed by continuous infusion cytarabine on days 1-4 with methotrexate IV on days 1-4 and methotrexate intrathecally on days 2 and 4. Patients receive GM-CSF subcutaneously beginning on day 6 and continuing until blood counts recover.
- At 6-8 weeks following the second course of consolidation therapy, patients receive a third consolidation course consisting of pegaspargase IV or IM on day 1.
- At 3-4 weeks following the third course of consolidation therapy, patients receive a fourth consolidation course consisting of cyclophosphamide IV on day 1.
- At 3 weeks following the completion of consolidation therapy, patients receive the same maintenance regimen as in Arm I.
Treatment continues in patients achieving complete response. Patients in both arms receive alternating sequences of maintenance therapy over 2 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90095-1678
- Jonsson Comprehensive Cancer Center, UCLA
-
Stanford, California, Forente stater, 94305-5750
- Stanford Cancer Center at Stanford University Medical Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Winship Cancer Institute of Emory University
-
-
New York
-
New York, New York, Forente stater, 10021
- Memorial Sloan-Kettering Cancer Center
-
Valhalla, New York, Forente stater, 10595
- New York Medical College
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Duke Comprehensive Cancer Center
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Taussig Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Diagnosis of one of the following malignancies:
- Acute lymphoblastic leukemia (ALL) of B- or T-cell lineage
- Philadelphia chromosome-positive ALL eligible
- Lymphoblastic lymphoma
- Chronic myelogenous leukemia in lymphoid blast crisis
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 20-100%
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Bilirubin no greater than 2.0 mg/dL
- Glucocorticoids for higher bilirubin allowed prior to entry, at principal investigator's discretion
Renal:
- Creatinine no greater than 2.0 mg/dL
- Glucocorticoids or renal radiotherapy for higher creatinine allowed prior to entry, at principal investigator's discretion
Cardiovascular:
- Left ventricular ejection fraction at least 50%
Other:
- Not pregnant
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior biologic therapy
Chemotherapy
- No prior chemotherapy
Endocrine therapy
- No prior endocrine therapy
Radiotherapy
- No prior radiotherapy
Surgery
- No prior surgery
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: ARA-C/High-Dose Mitoxantrone("All-2")
See detail description
|
|
Aktiv komparator: Standard Vincristine/Prednisone ("L-20")
See detail description
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Complete Remission (CR)
Tidsramme: 2 years
|
complete remission (CR) Disappearance of all clinical evidence of leukemia for a minimum of four weeks.
The patient should have a neutrophil count > 1,000 x 10^6/1, a platelet count > 100,000 x 10^9/1, no circulating blasts, and < than or = to blasts on bone marrow differential in a qualitatively normal or hypercellular marrow.
Progressive disease or failure: Increasing bone marrow infiltrate or development of organ failure or extramedullary infiltrates due to leukemia.
|
2 years
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Nicole Lamanna, MD, Memorial Sloan Kettering Cancer Center
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- B-celle akutt lymfatisk leukemi hos voksne
- blastisk fase kronisk myelogen leukemi
- kronisk myelogen leukemi, BCR-ABL1 positiv
- stadium III voksen lymfatisk lymfom
- stadium IV voksen lymfatisk lymfom
- ikke-sammenhengende stadium II voksen lymfatisk lymfom
- ubehandlet akutt lymfatisk leukemi hos voksne
- sammenhengende stadium II voksen lymfatisk lymfom
- stadium I voksen lymfatisk lymfom
- T-celle akutt lymfatisk leukemi hos voksne
- stadium II voksen lymfatisk lymfom
Ytterligere relevante MeSH-vilkår
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesykdommer
- Immunproliferative lidelser
- Leukemi, lymfoid
- Lymfom
- Leukemi
- Forløpercelle lymfoblastisk leukemi-lymfom
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Agenter fra det perifere nervesystemet
- Antivirale midler
- Nukleinsyresyntesehemmere
- Enzymhemmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler
- Antirevmatiske midler
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Antineoplastiske midler, fytogene
- Topoisomerase II-hemmere
- Topoisomerasehemmere
- Dermatologiske midler
- Antibakterielle midler
- Proteinsyntesehemmere
- Antibiotika, antineoplastisk
- Reproduktive kontrollmidler
- Abortfremkallende midler, ikke-steroide
- Aborterende midler
- Folsyreantagonister
- Cyklofosfamid
- Etoposid
- Prednison
- Doxorubicin
- Liposomal doksorubicin
- Cytarabin
- Metotreksat
- Vincristine
- Daunorubicin
- Mitoksantron
- Merkaptopurin
- Carmustine
- Sargramostim
- Pegaspargase
- Dactinomycin
Andre studie-ID-numre
- 96-015
- P30CA008748 (U.S. NIH-stipend/kontrakt)
- MSKCC-96015A1
- NCI-V96-0881
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på cyklofosfamid
-
The Christie NHS Foundation TrustAvsluttetCD19 Positivt Non-Hodgkin lymfomStorbritannia
-
Uprety ShraddhaPostgraduate Institute of Medical Education and ResearchUkjent
-
Yonsei UniversityFullførtBrystkreftKorea, Republikken
-
National Institute of Blood and Marrow Transplant...UkjentAplastisk anemi IdiopatiskPakistan
-
Lagos State UniversityUkjentHematologisk abnormitetNigeria
-
University of Alabama at BirminghamGenentech, Inc.; Ortho Biotech, Inc.FullførtInvasiv brystkreftForente stater
-
German Breast GroupGerman Adjuvant Breast Cancer GroupFullført
-
Auxilio Mutuo Cancer CenterUkjentInfiltrerende kanal- og lobulært karsinom in situ | Invasiv lobulært brystkarsinom | Inflammatorisk brystkarsinomPuerto Rico
-
Memorial Sloan Kettering Cancer CenterFullførtNon-Hodgkins lymfom | CNS lymfom | CNS hjernekreftForente stater